Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients is a research paper published in Expert Review of Anticancer Therapy (2012). On theSindex it has a DataRank of 1.6. It has been cited 23 times, with 21 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.477
From this paper's citation signal
Citation Network Contribution
1.1
From 19 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 21 citers.
MeSH Terms